Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00611689 · ClinicalTrials.gov registry record · Phase 1
Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors
A Phase 1 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00611689 is a Phase 1 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 45 participants.
The verdict
NCT00611689, a Phase 1 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
In this phase I study, the investigators will determine the maximum tolerated doses of imatinib and PTK/ZK administered in two different dose schedules. Due to the different mechanisms of action and the minimally-overlapping toxicity profiles of these two novel oral agents, it is hoped that a combination regimen incorporating both compounds will produce increased activity without enhanced toxicity. After completion of this phase I study, the investigators propose a follow-up phase II study in patients with previously treated metastatic renal cell cancer - where VEGF and PDGF appear to play important roles in the malignant phenotype - to determine the antitumor efficacy of the recommended dose of this combination regimen.
Interventions
- DRUG Imatinib and PTK/ZK222584
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2004-07 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00611689
The ClinicalTrials.gov registry entry for NCT00611689 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Imatinib and PTK/ZK222584 is the first listed.
NCT00611689 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00611689 about?
NCT00611689 is a clinical study titled "Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors". In this phase I study, the investigators will determine the maximum tolerated doses of imatinib and PTK/ZK administered in two different dose schedules. Due to the different mechanisms of action and the minimally-overlapping toxicity profiles of these two novel oral agents, it is hoped that a combin...
What is the current status of trial NCT00611689?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2004-07. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00611689?
The interventions under investigation include: Imatinib and PTK/ZK222584 (DRUG).
Who is sponsoring clinical trial NCT00611689?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.